Michael Papagikos
Expertise in
36
conditions

Dr. Michael Papagikos

Radiation Oncology
1988 S 16th St, 
Wilmington, NC 
Offers Telehealth
25 Years of Experience
Expertise in
36
conditions
1988 S 16th St, 
Wilmington, NC 

Overview

Michael Papagikos is a Radiation Oncologist in Wilmington, North Carolina. Dr. Papagikos has been practicing medicine for over 25 years is highly rated in 36 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Lung Cancer, and Pleuropulmonary Blastoma.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Wake Forest University School Of Medicine, 2001.0

Residency

Wake Forest School of Medicine

Specialties

Radiation Oncology

Licenses

Radiology in NC

Board Certifications

Radiation Oncology

Hospital Affiliations

Novant Health New Hanover Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Coastal Carolina Radiation Oncology - Wilmington
1988 S 16th St, Wilmington, NC 28401

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Radiation
Study Phase: Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Enrollment Status: Unknown
Publish Date: June 12, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Etoposide, Carboplatin
Study Phase: Phase 3
View 10 Less Clinical Trials

7 Total Publications

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 14, 2023
Similar Doctors
Michael Nichols
Expertise in
38
conditions
Dr. Michael Nichols
Radiation Oncology
Expertise in
38
conditions
Dr. Michael Nichols
Radiation Oncology

Coastal Carolina Radiation Oncology - Wilmington

1988 S 16th St, 
Wilmington, NC 
 (0.1 miles away)
910-662-8440
Experience:
23+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Nichols is a Radiation Oncologist in Wilmington, North Carolina. Dr. Nichols has been practicing medicine for over 23 years is highly rated in 38 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Posterior Fossa Tumor, and Small Cell Lung Cancer (SCLC).

Expertise in
50
conditions
Dr. Patrick D. Maguire
Radiation Oncology
Expertise in
50
conditions
Dr. Patrick D. Maguire
Radiation Oncology

Coastal Carolina Radiation Oncology PLLC

1988 S 16th St, 
Wilmington, NC 
 (0.1 miles away)
910-662-8440
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Maguire is a Radiation Oncologist in Wilmington, North Carolina. Dr. Maguire is highly rated in 50 conditions, according to our data. His top areas of expertise are Familial Prostate Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Posterior Fossa Tumor. Dr. Maguire is currently accepting new patients.

Tiffany Morgan
Expertise in
39
conditions
Dr. Tiffany Morgan
Radiation Oncology
Expertise in
39
conditions
Dr. Tiffany Morgan
Radiation Oncology

Coastal Carolina Radiation Oncology - Wilmington A

1988 S 16th St, Ste A, 
Wilmington, NC 
 (0.1 miles away)
910-662-8440
Experience:
12+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tiffany Morgan is a Radiation Oncologist in Wilmington, North Carolina. Dr. Morgan has been practicing medicine for over 12 years is highly rated in 39 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Posterior Fossa Tumor.

Frequently Asked Questions about Dr. Michael Papagikos

How do I make an appointment with Dr. Michael Papagikos?

You can book an appointment with Dr. Michael Papagikos by calling their office at 910-662-8440. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael Papagikos a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael Papagikos is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael Papagikos specialize in?

While Dr. Michael Papagikos is a Radiation Oncology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Michael Papagikos participate in research or clinical trials?

Yes. Dr. Michael Papagikos has published 7 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Michael Papagikos's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael Papagikos accept my insurance?

Dr. Michael Papagikos accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 910-662-8440 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Papagikos's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile